Table II.
Outcome Analysis (PFS, DFS, and OS) for All Patients Across Treatment Groups
| Treatment Group | Survival (%) at 5 years | ||
|---|---|---|---|
| PFS | OS | DFS | |
| 3-4 R-CHOP (n=17) | 93.8 | 100 | 93.8 |
| 3-4 R-CHOP+RT (n=147) | 89.2 | 93.5 | 93.9 |
| 6 R-CHOP (n=48) | 79.9 | 84.5 | 92.9 |
| 6 R-CHOP+RT (n=50) | 89.8 | 97.8 | 89.8 |
R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; RT, radiotherapy; PFS, progression-free survival; OS, overall survival; DFS, disease-free survival.